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Purpose: This study aimed to validate and update a model for predicting the risk of axillary lymph 
node (ALN) metastasis for assisting clinical decision-making. 
Methods: We included breast cancer patients diagnosed at six Dutch hospitals between 2011 and 
2015 to validate the original model which includes six variables: clinical tumor size, tumor grade, 
estrogen receptor status, lymph node longest axis, cortical thickness and hilum status as detected by 
ultrasonography. Subsequently, we updated the original model using generalized linear model (GLM) 
tree analysis and by adjusting its intercept and slope. The area under the receiver operator 
characteristic curve (AUC) and calibration curve were used to assess the original and updated models. 
Clinical usefulness of the model was evaluated by false-negative rates (FNRs) at different cut-off 
points for the predictive probability. 
Results: Data from 1,416 patients were analyzed. The AUC for the original model was 0.774. Patients 
were classified into four risk groups by GLM analysis, for which four updated models were created. 
The AUC for the updated models was 0.812. The calibration curves showed that the updated model 
predictions were better in agreement with actual observations than the original model predictions. 
FNRs of the updated models were lower than the preset 10% at all cut-off points when the predictive 
probability was less than 12.0%. 
Conclusions: The original model showed good performance in the Dutch validation population. The 
updated models resulted in more accurate ALN metastasis prediction and could be useful preoperative 
tools in selecting low-risk patients for omission of axillary surgery. 

















Axillary lymph node (ALN) status is an important prognostic factor and a major determinant for 
postoperative treatment decision-making for breast cancer patients1,2. ALN staging evolved together 
with the shift in surgical treatment from the largest tolerable surgery to less invasive surgery. During 
this process, sentinel lymph node biopsy (SLNB) replaced ALN dissection and has become the 
standard of care for ALN staging in breast cancer patients with clinically negative ALN for over 10 
years. SLNB has significantly reduced the incidence of surgical complications such as upper limb 
lymphedema and impaired shoulder function, and has improved patients’ quality of life without 
compromising their survival3–7. However, the surgical complications from SLNB cannot be ignored. 
Lymphedema occurs in approximately 5-8% of patients receiving a SLNB and paresthesia in 10-15%6–
12
. In addition, 28-49% of the patients experience shoulder-arm function impairment11–13. Notably, 60-
70% of the patients receiving a SLNB are shown to have negative SLNs after histopathological 
analysis and thus do not benefit from the procedure4,14,15. 
Due to early detection through the national screening program, more patients are being diagnosed 
with early breast cancer and are more often free from ALN metastasis16. If patients with a 
pathologically negative ALN can be preoperatively predicted, omission of axillary surgery could avoid 
the above-mentioned surgical complications and improve their quality of life, without affecting the 
postoperative treatment decision-making. Consequently, accurate assessment of the preoperative 
patients’ risk of ALN metastasis is required. However, all currently used imaging modalities have low 
sensitivity in predicting ALN metastasis, resulting in a false-negative prediction of around 40-70%17–20. 
Therefore, new tools for prediction of preoperative ALN metastasis are urgently needed. 
We previously developed a predictive model for ALN metastasis in a Chinese breast cancer population 
based on clinicopathological features from the primary tumor and axillary ultrasound21. The model was 
based on six independent predictors for ALN metastasis: clinical tumor size, histological tumor grade, 
estrogen receptor (ER) status, longest axis, cortical thickness and hilum status of the ALN as detected 
by ultrasonography. The model was validated on an additional set of 234 Chinese patients, generating 
an area under the receiver operating characteristic curve (AUC) of 0.86421, indicating a good 
performance in ALN metastasis prediction. 
In this study we validated the performance of the Chinese model for predicting ALN metastasis in a 















data in order to improve its discriminative performance and predictive accuracy and maintain its 
generalizability in different ethnic groups.  
Methods 
Patients 
We selected all women with primary breast cancer who underwent breast surgery and axillary staging 
at six participating Dutch hospitals (one university hospital, two teaching and referral hospitals and 
three general hospitals) between 2011 and 2015 from the Netherlands Cancer Registry (NCR). The 
NCR records data on all cancer patients in the Netherlands. The inclusion and exclusion criteria were 
the same with that used in the initial study which developed the model21. Patients with one or more 
ALN(s) detected by a preoperative ultrasound and receiving either a SLNB or ALN dissection were 
included in this study, irrespective whether the ALNs were palpable or not. Exclusion criteria were use 
of primary systemic therapy, ductal carcinoma in situ and bilateral breast cancer. Patients with lymph 
node cortical thickness larger than 2.3mm as measured by ultrasound received a final needle 
aspiration cytology (FNAC) according to Dutch guideline22. In addition to the Dutch patients, the 
Chinese patients (n=322) diagnosed at Cancer Hospital of Shantou University Medical College 
between 2009 and 2014 for developing the model were also used in the present study for updating the 
original model21. This study was approved by all participating hospitals.  
Data collection 
From the NCR we collected data on age at diagnosis, menopausal status, tumor location, histological 
grade, ER, progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) and 
pathological ALN status. Data on histological grade, ER, PgR and HER2 status were obtained from 
surgical resection specimens. Data on clinical tumor size of the primary tumor, and longest axis, 
cortical thickness and hilum status of the ALN were obtained from measurements by high frequency 
ultrasound (>10MHz). The ultrasound reports and images were initially checked by one author (M.A.) 
after receiving training from a radiologist (M.D.D.). In case of uncertainty the image was reviewed by a 
radiologist of the participating hospital. All researchers involved in the data collection were blinded to 
the pathological ALN status of the patients. 
Staging was coded according to the Tumor, Node and Metastasis (TNM) classification23. Tumor grade 















categorized as described previously21. Both ER and PgR status were divided into four categories: - 
(<10%), + (10-25%), ++ (25-75%) and +++ (>75%)21. Since the NCR registered the ER and PgR 
status in 10% steps (0, 10%, 20%, etc.), we replaced the second cut-off point (25%) with 30% and the 
third (75%) with 80%. Variables related to ALNs were measured on the most suspicious lymph node 
detected by ultrasonography, which was defined as the lymph node with the thickest cortex and/or 
absence of a hilum. A lymph node was defined as positive if macrometastases, micrometastases or 
isolated tumor cells (ITCs) were identified by histopathological analysis21. 
Statistical analysis 
Differences of categorical and continuous variables between groups were analyzed using the Chi-
square and Mann-Whitney U test, respectively. The clinical value for each predictor in the original 
model was used to calculate the ALN metastasis probability for each patient in the present study. The 
AUC was used to evaluate the discriminative performance of the model. For the calibration of the 
original model, the enrolled Dutch patients were sorted on their predicted probability and grouped into 
three equally sized groups. For each group, the mean model-predicted probability and the actual 
percentage (95% confidence interval [CI]) of ALN metastasis were calculated. A calibration plot was 
drawn showing the mean model-predicted probability against the actual percentage of ALN 
metastasis, providing information about the predictive accuracy of the model for each group. 
To improve its discriminative performance and predictive accuracy, we updated the original model 
using both the Dutch and the Chinese populations as follows. Generalized linear model (GLM) tree 
analysis was applied to the Dutch and Chinese patient populations to classify patients into groups with 
different risk of ALN metastasis based on their clinicopathological characteristics. In each group, the 
model was updated separately by adjusting the intercept and slope of the original model. Detailed 
information on GLM tree analysis is provided in the Supplementary Methods. The AUC and calibration 
plot were used to assess the discriminative performance and predictive accuracy of the updated 
models. False-negative rates (FNRs) of the updated models at several cut-off points for the predicted 
probability were calculated to assess their clinical usefulness. FNR was considered acceptable if it 
was lower than 10%. All statistical tests were two-sided, and a P-value <0.05 was considered to be 
statistically significant. Statistical analyses were performed using the statistical software SPSS, 

















In total, 1,416 out of 2,227 Dutch breast cancer patients were included (Fig.1). Based on Dutch 
guideline, 468 patients would have received a FNAC before they received any axillary surgery22. The 
comparison of clinicopathological features between the Dutch and Chinese patients is shown in Table 
1. All features, except for longest axis of ALN, differed significantly between the two patient 
populations (P<0.05). The median age of the Dutch patients was 11 years older than the Chinese 
patients. Dutch patients had a smaller median tumor size and cortical thickness of ALN compared to 
Chinese patients. A larger proportion of Dutch patients had ER and PgR positive, HER2 negative and 
low histologically graded tumors. In addition, a smaller proportion of the Dutch patients lacked a hilum 
compared to the Chinese patients. ALN metastasis was identified in 354 (25.0%) of the Dutch patients. 
Of these patients, 318 (89.8%) patients had macrometastases and 36 (10.2%) patients had 
micrometastases or ITCs. Comparison of patients’ characteristics among the six Dutch hospitals is 
shown in Table S1. 
Discrimination performance and predictive accuracy of the original Chinese model 
The AUC of the original model was 0.774 (95% CI 0.743-0.804) when it was applied to the entire 
Dutch population (Fig. 2a), whereas the AUCs for each hospital ranged from 0.705 to 0.848 (Fig. S1). 
The mean model-predicted probability and the actual percentage of patients with ALN metastasis for 
each group are shown in Table S2. In all groups, except for group 1 (ALN metastasis low-risk group) 
including patients with a mean model-predicted probability lower than 10.0%, the mean model-
predicted probabilities were within the 95% CI of the actual percentage of patients with ALN 
metastasis. In Fig. 2b, the calibration plot showed less optimal agreement between the model 
prediction and the actual observation, especially for group 1. 
Update of the original model  
GLM tree analysis identified two variables (cortical thickness of ALN and clinical tumor size) for 
partitioning patients according to their ALN status. The identified cut-off points maximized the 
separation of risk-specific ALN metastasis. The patients were classified into four groups with 
increasing rates of ALN metastasis. Patients with cortical thickness ≤3.1mm and clinical tumor size 















had the highest rate (70.2%) of ALN metastasis (Fig. 3). The updated models for each group are 
shown in Table S3.  
Discrimination performance and predictive accuracy of the updated models 
Based on the GLM tree analysis, the Dutch validation patients were first classified into different groups 
according to their ALN cortical thickness and clinical tumor size of the primary tumor. Subsequently, 
their predicted probabilities of ALN metastasis were calculated using the corresponding updated model 
for each group (Table S3). The AUC of the updated models for the entire Dutch patient population was 
0.812 (95% CI 0.784-0.840) (Fig. 2c). The AUCs of the updated models for each hospital ranged from 
0.730 to 0.874, which were all higher than the corresponding AUCs of the original model (Fig. S1 and 
S2). The mean model-predicted probability and the actual percentage of patients with ALN metastasis 
for each group are shown in Table S4. In all groups, the model-predicted probabilities were within the 
95% CI of the actual percentage of patients with ALN metastasis, showing better predictive accuracy 
compared with the original model, especially for group 1 (Table S2 and S4). The calibration plot for the 
updated models showed almost perfect agreement between the model prediction and the actual 
observation (Fig. 2d). 
Clinical usefulness of the updated models 
FNRs of the updated models at several model-predicted probability cut-off points are shown in Table 2. 
By using cut-off points, we considered patients with a model-predicted probability less than or equal to 
the cut-off point to have negative ALNs. Since the generally accepted FNR for SLNB was 10.0%, we 
considered this percentage acceptable in our study. Using this criterion, the FNR of the updated 
models (7.9%) was acceptable when the model-predicted probability cut-off point was set at 12.0%. 
Using the updated models, 415 patients (29.3% of entire study population) could have been selected 
for axillary surgery omission. When combined with FNAC for those patients with lymph node cortical 
thickness larger than 2.3mm, the FNR of our model could have been reduced to 6.2%. 
Discussion 
In this study we validated and updated a previously developed model21, providing a reliable tool for 
preoperative assessment of the risk of ALN metastasis. This tool could assist clinicians in determining 
the optimal treatment strategy of axillary staging for individual patients.  















compared with the Chinese patients. This disparity could partly be due to the different ethnic 
backgrounds of the two study populations25. In addition, the routinely performed nationwide screening 
programme in the Netherlands (which is absent in China) may be another contribution to this 
difference, since this leads to an increasing number of early diagnoses26. Despite the differences in 
clinicopathological features between the two study populations, the original model already showed a 
good discriminative performance with an AUC of 0.774. This indicates a good generalizability of the 
model to patients of different ethnic origins. However, the original model underestimated the ALN 
metastasis probability in the low-risk Dutch patient group with an ALN metastatic rate of 10.0%; a 
similar underestimation was found in the Chinese study21. Moreover, these results may indicate that 
different models for different ALN metastasis risk groups are required to improve the prediction. In 
order to refine the predictive accuracy of the model in several risk-based subgroups and maintain 
generalizability to different ethnic groups, we performed GLM tree analysis using data of both the 
Dutch and Chinese patients. After creating different risk groups, the discriminative performance and 
predictive accuracy of the updated models improved in the Dutch patients, especially for low-risk 
patients with a mean model-predicted probability lower than 10.0%. In a sensitivity analysis, the 
updated models performed well in the Chinese patients (n=322) as well (AUC=0.851 [95%CI, 0.808-
0.894], data not shown). These results emphasize the stability of the model in ALN metastasis 
prediction. 
SLNB remains the standard of care for axillary staging in patients with clinically negative nodes. In 
order to avoid its complications, omission of axillary surgery in ALN metastasis low-risk patients has 
gained more interest. Several ongoing clinical trials are investigating this topic27. Most of these trials 
enrol patients based on a preoperative ultrasound with or without FNAC. However, the FNR of ALN 
metastasis prediction by a preoperative ultrasound has been reported to be as high as around 30-
55%17–19,28. Other imaging modalities e.g. magnetic resonance imaging (MRI) or positron emission 
tomography-computed tomography (PET-CT) have also been reported to predict the risk of ALN 
metastasis with a high FNR (MRI 18% vs PET-CT 36%)29. Moreover, these imaging modalities are too 
expensive to be applied for every patient.  
Two models predicting the risk of ALN metastasis have been described in literature. The Memorial 
Sloan Kettering Cancer Center (MSKCC) model, in which 3,786 patients receiving SLNB were 















an AUC of 0.754 in ALN metastasis prediction when applied to a validation cohort with 1,545 
patients30. Recently, another predictive model was reported for patients with negative axillary 
ultrasound. Comparable to the MSKCC model and our model, this model demonstrated good 
discrimination with AUC of 0.731 and 0.79 when validated internally and externally, respectively31. A 
disadvantage of these two models is that data for some variables, e.g. lymphovascular invasion, 
cannot be obtained preoperatively. This will hamper their clinical application as a preoperative 
predictive model. 
To the best of our knowledge, this is the first model that predicts the risk of ALN metastasis in patients 
with ALNs detected by a preoperative ultrasound. For most of these patients, it is very difficult to judge 
whether the detected lymph nodes are malignant or not, merely based on their ultrasound morphology. 
Clinically, a FNAC is performed when suspicious lymph nodes are found. The FNR of ALN metastasis 
prediction by FNAC is higher than 20%32. In contrast, our updated models had a lower FNR (7.9%) in 
predicting the ALN status when the cut-off point was set at 12.0%. More importantly, this FNR is even 
lower when combined with a FNAC. These results suggest that axillary surgery omission could be 
possible for patients with a predicted probability lower than 12.0% by using the updated models, 
especially when combined with FNAC; this group accounts for 29.3% of the entire patient cohort in this 
study. These findings underscore the potential clinical value of the updated models in assisting clinical 
decision making for the selection of ALN metastasis low-risk patients who could be spared axillary 
surgery. For these low-risk patients, we would still suggest to perform a FNAC according to clinical 
standard of care management. 
The International Breast Cancer Study Group (IBCSG) 23-01 trial was designed to determine whether 
omission of ALND was warranted in patients with one or more micrometastatic (≤2mm) SLNs and a 
primary tumor size ≤5cm. Results of this trial support the omission of ALND in patients with 
micrometastases in SLNs33. However, the risk of leaving micrometastases or ITCs in patients without 
removing any ALNs is unclear. Therefore, in this study, we considered ALNs with micrometastases or 
ITCs as positive, similar to our previous study21. Only 36 patients had ALNs with micrometastases or 
ITCs. Therefore, we expected it not to have influenced the predictive and discriminative performance 
of our updated models in predicting ALN macrometastasis (>2mm). This was confirmed by results of a 
sensitivity analysis where we included patients with ALN macrometastasis only, resulting in an AUC of 















This study has several strengths. First, it is a multicenter validation study. The six participating 
hospitals are from different areas of the Netherlands. Therefore, the enrolled patients in our study are 
representative for the whole breast cancer population in the Netherlands. Our updated models show a 
very good discriminative performance in all participating hospitals, indicating good generalizability of 
the models. Second, the necessary data for all of the six variables incorporated in our models can be 
obtained preoperatively, for example, by a core needle biopsy of the primary tumor and axillary 
ultrasound examination. This would facilitate the application of our models. Third, our updated models 
are easy to use. After all the necessary data for the six variables are obtained, patients can be 
grouped into one of the different risk groups based on their cortical thickness of the lymph node 
detected by ultrasound and the clinical tumor size, as shown in Fig.3. Subsequently, the probability of 
ALN metastasis for an individual patient can be calculated using the corresponding formula 
demonstrated in Table S3. A user-friendly web-based calculator based on our updated models has 
been developed and will be published online to facilitate the use of our models 
(https://www.evidencio.com/models/show/999).  
There are limitations of this study. First, the ER status and grade of the primary tumor were obtained 
from surgical specimens and not from core needle biopsies in our study. Since breast cancer is highly 
heterogeneous, discrepancies between the ER status and tumor grade of core needle biopsies and 
the whole surgical specimen may arise. Several studies have demonstrated that the discrepancy of 
ER positive rates analysis on core needle biopsies and subsequent excision specimen from the same 
patient was only 2-3%34,35. We therefore do not expect that this influences the model validity. However, 
discrepancy of tumor grade between core needle biopsies and excision specimen was reported to be 
near 30% in a recent meta-analysis36. It may be that this discrepancy has influence on the 
performance of the model. However, it is not clear whether this will also influence the FNR of the 
models in predicting ALN metastasis low-risk patients. Second, the FNR (7.9%), which we considered 
might be suitable for selecting patients to avoid axillary surgery, was calculated on the basis of FNR of 
SLNB from 75.0% of patients received SLNB only. This means that the real FNR of our model is 
higher than 7.9% and theoretically lower than 17.9%. Given the improvement of systemic treatments 
for breast cancer, the impact of residual metastatic disease in ALNs on survival of patients has 
become less important. This has been proved by results from IBCSG 23-01 and Z0011 trials, which 















ALND group without affecting patients’ long term recurrence and survival33,37. Third, the axillary 
ultrasound is an operator-dependent technique. Measurement of the three ultrasound variables 
incorporated in our models may differ when performed by different doctors due to inter-observer 
variability. However, an experienced radiologist can almost always identify ALNs and access their 
morphology if they are present28,38,39. Therefore, we recommend an experienced radiologist to assess 
the ALN when using our models. Finally, this is a study based on retrospectively collected data from a 
cancer registry. Harmonization of data measurement was less optimal. Nevertheless, data was 
uniformly collected by trained data managers according to strict coding manuals. Together, a validation 
of our models using core needle biopsies in each center is recommended before using the models in 
clinical practice to assist decision-making on surgical treatment of the axilla. 
Conclusions  
We successfully validated and updated our previously published model in a multicenter Dutch breast 
cancer population. The original model showed good performance in the Dutch population. The 
updated models resulted in more accurate ALN metastasis predictions and could therefore be useful 
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Table 1. Comparison between the Dutch and Chinese patients by clinicopathological characteristics 
 





Total patients No. 1,416 (100) 322 (100) - 
Age at diagnosis (year) 
Median (IQR) 
. 
61 (52, 69) 
 















Tumor size (cm) 
  Median (IQR) 
 
1.5 (1.0, 2.2) 
 
3.0 (2.2, 4.0) 
<0.001 
 




T2 (≤ 3cm) 

























































































































Longest axis (mm) 
Median (IQR) 
 
12.6 (9.6, 16.9) 
 
13.0 (10.0, 17.0) 
0.70 
 
Cortical thickness (mm) 
Median (IQR) 
 
1.9 (1.3, 2.8) 
 
4.0 (3.0, 6.0) 
<0.001 
 











Lymph node metastasis 
   Yes 










Abbreviations: ALND: axillary lymph node dissection; ER, estrogen receptor; HER2, 
human epidermal growth factor receptor 2; IQR, interquartile range; LIQ, lower inner 
quadrant; LOQ, lower outer quadrant; PgR, progesterone receptor; SLNB: sentinel 
















Table 2. FNRs of the updated models at different model-predicted probability cut-off points 
 
Cut-off point No. of patients (%) No. of patients with ALNM FNR (%) 
5% 255 (18.0) 10 2.8 
10% 281 (19.7) 13 3.7 
11% 323 (22.8) 15 4.2 
12% 415 (29.3) 28 7.9 
13% 463 (32.7) 37 10.5 
14% 540 (38.1) 44 12.4 
















Supplementary Table 1 Comparison of clinicopathological characteristics among six hospitals in the validation 
group   
 












No. of patients 204 (100) 355 (100) 108 (100) 287 (100) 300 (100) 162 (100) 
Age at diagnosis (year) 
Median (IQR) 
 
63 (53, 71) 
 
61 (52, 69) 
 
62 (54, 70) 
 
61 (52, 69) 
 
61 (51, 69) 
 






















Tumor size (cm) & 































































































24 (14.8)  

























































































































































































































Lymph node metastases 
&
 
  Yes 



















ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; IQR: interquartile range, which is the 25th 
percentile and the 75th percentile; LIQ: lower inner quadrant; LOQ: lower outer quadrant; PR: progesterone receptor; 
UIQ: upper inner quadrant; UOQ: upper outer quadrant; 
& Significantly different from at least one other patient set;  
















Supplementary Table 2. Actual versus predicted rate of axillary lymph node metastasis for the original model 
 
Group Patient number Proportion of ALN metastasis 
Actual % (95% CI) Mean predicted % 
1 472 10.0 (7.3-12.7) 6.8 
2 472 17.6 (14.1-21.0) 18.9 
3 472 47.5 (42.9-52.0) 51.3 
















Supplementary Table 3. Correction factor for slope, new intercept and updated model for each group classified by 
GLM tree analysis 
 
Group Correction 






0.1406 -3.6344 ln p/1-p = 0.0089*a + 0.0389*b + 0.1997*c + 0.2112 (d1) + 0.2939 (d2) 
+ 0.0429*e + 0.0533*f - 3.6344 
2 
 
0.2451 -2.7284 ln p/1-p = 0.0154*a + 0.0679*b + 0.3480*c + 0.3681 (d1) + 0.5123 (d2) 
+ 0.0748*e + 0.0929*f - 2.7284 
3 
 
0.6454 -4.0356 ln p/1-p = 0.0407*a + 0.1788*b + 0.9165*c + 0.9694 (d1) + 1.3489 (d2) 
+ 0.1968*e + 0.2446*f – 4.0356 
4 
 
0.8074 -4.0805 ln p/1-p = 0.0509*a + 0.2236*b + 1.1465*c + 1.2127 (d1)+ 1.6875 (d2) 
+ 0.2463*e + 0.3060*f – 4.0805 
Abbreviations: GLM: Generalized linear model, a: longest axis of lymph nodes, continuous variable, b: cortical 
thickness of lymph nodes, continuous variable, c: hilum of lymph nodes, c=0 when presence and c=1 when 
absence, d1 and d2: d1=1 and d2=0 when histological tumor grade 2, d1=0 and d2=1 when histological tumor 
grade 3, e: clinical tumor size, continuous variable, f: tumor estrogen receptor status, f=0 when ER is negative, 
f=1 when ER+, f=2 when ER2+ and f=3 when ER3+, p in the formulas: the predictive probability of axillary lymph 
















Supplementary Table 4. Actual versus predicted rate of axillary lymph node metastasis for the updated models 
 
Group Patient number Proportion of ALN metastasis 
Actual % (95% CI) Mean predicted % 
1 472 7.8 (5.4-10.3) 7.4 
2 472 16.3 (13.0-19.7) 15.7 
3 472 50.8 (46.3-55.4) 50.7 
Abbreviations: ALN, axillary lymph node; CI, confidence interval 
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